These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10853014)

  • 1. Expression of the SART1 tumor-rejection antigen in human osteosarcomas.
    Ishida H; Komiya S; Inoue Y; Yutani S; Inoue A; Itoh K
    Int J Oncol; 2000 Jul; 17(1):29-32. PubMed ID: 10853014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the tumor-rejection antigen SART1 in brain tumors.
    Imaizumi T; Kuramoto T; Matsunaga K; Shichijo S; Yutani S; Shigemori M; Oizumi K; Itoh K
    Int J Cancer; 1999 Dec; 83(6):760-4. PubMed ID: 10597192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas.
    Yutani S; Shichijo S; Inoue Y; Kawagoe N; Okuda K; Kurohiji T; Tanaka M; Sata M; Itoh K
    Oncol Rep; 2001; 8(2):369-72. PubMed ID: 11182058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides.
    Tsuda N; Murayama K; Ishida H; Matsunaga K; Komiya S; Itoh K; Yamada A
    J Orthop Res; 2001 May; 19(3):346-51. PubMed ID: 11398844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
    Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
    Urol Res; 2000 Jun; 28(3):178-84. PubMed ID: 10929426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the SART1 tumor-rejection antigens in colorectal cancers.
    Sasatomi T; Yamana H; Shichijo S; Tanaka S; Okamura T; Ogata Y; Itoh K; Shirouzu K
    Dis Colon Rectum; 2000 Dec; 43(12):1754-8. PubMed ID: 11156463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
    Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
    Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.
    Kumamaru W; Nakamura S; Kadena T; Yamada A; Kawamura E; Sasaki M; Ohyama Y; Toyoshima T; Hayashida JN; Itoh K; Shirasuna K
    Int J Cancer; 2004 Feb; 108(5):686-95. PubMed ID: 14696095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma.
    Tsukahara T; Kawaguchi S; Torigoe T; Kimura S; Murase M; Ichimiya S; Wada T; Kaya M; Nagoya S; Ishii T; Tatezaki S; Yamashita T; Sato N
    Cancer Sci; 2008 Feb; 99(2):368-75. PubMed ID: 18271936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the SART-1 antigens in uterine cancers.
    Matsumoto H; Shichijo S; Kawano K; Nishida T; Sakamoto M; Itoh K
    Jpn J Cancer Res; 1998 Dec; 89(12):1292-5. PubMed ID: 10081490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
    Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
    Int J Cancer; 1999 May; 81(3):459-66. PubMed ID: 10209962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the SART3 antigens in oral cancers.
    Fukuda K
    Kurume Med J; 2001; 48(1):55-8. PubMed ID: 11402621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24.
    Katsura F; Eura M; Chikamatsu K; Oiso M; Yumoto E; Ishikawa T
    Jpn J Clin Oncol; 2000 Mar; 30(3):117-21. PubMed ID: 10798537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of tumor-rejection antigens in gynecologic cancers.
    Tanaka S; Tsuda N; Kawano K; Sakamoto M; Nishida T; Hashimoto T; Shichijo S; Kamura T; Itoh K
    Jpn J Cancer Res; 2000 Nov; 91(11):1177-84. PubMed ID: 11092984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
    Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the SART3 tumor rejection antigen in renal cell carcinoma.
    Kawagoe N; Shintaku I; Yutani S; Etoh H; Matuoka K; Noda S; Itoh K
    J Urol; 2000 Dec; 164(6):2090-5. PubMed ID: 11061933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
    Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
    Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of human leukocyte antigen-A26-restricted and tumor-specific cytotoxic T lymphocytes by a single peptide of the SART1 antigen in patients with cancer with different A26 subtypes.
    Inoue Y; Nakao M; Matsunaga K; Kikuchi M; Gomi S; Toh U; Takamori S; Yamana H; Itoh K
    J Immunother; 2000; 23(3):296-303. PubMed ID: 10838658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of SART3 tumor-rejection antigen in gastric cancers.
    Niiya F; Nishizaka S; Matsunaga K; Koufuji K; Mori M; Katai H; Yamana H; Itoh K
    Jpn J Cancer Res; 2000 Mar; 91(3):337-42. PubMed ID: 10760694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.